PRME · NASDAQ
Prime Medicine (PRME) Stock Price & Fundamentals
Prime Medicine (PRME) closed at $767.79 on Oct 9, 2026, down 0.26% from the previous close of $769.78.
Share price, past year
1Y +13.09%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $767.79 |
| Sep 30, 2026 | $748.60 |
| Aug 31, 2026 | $708.79 |
| Jul 31, 2026 | $699.48 |
| Jun 30, 2026 | $685.62 |
| May 29, 2026 | $722.68 |
| Apr 30, 2026 | $731.84 |
| Mar 31, 2026 | $700.50 |
| Feb 27, 2026 | $686.90 |
| Jan 30, 2026 | $695.62 |
| Dec 31, 2025 | $667.90 |
| Nov 28, 2025 | $709.66 |
| Oct 31, 2025 | $701.19 |
Key statistics
- Market cap
- $138.77B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $4.63M
- Net income (TTM)
- −$187.89M
- Shares outstanding
- 180.7M
- Dividend yield
- —
- 52-week range
- $662.45 – $770.46
Prime Medicine's market cap is $138.77B, based on a share price of $767.79 and 180.7M shares outstanding as of Jun 30, 2026.
Financials
Prime Medicine reported revenue of $4.63M for fiscal 2025, up 55.28% from fiscal 2024.
Prime Medicine reported a net loss of $201.14M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $4.63M | +55.3% | −$201.14M | −4,342.4% | −$1.35 | −$167.10M |
| FY2024ended Dec 31, 2024 | $2.98M | — | −$195.88M | −6,566.6% | −$1.65 | −$130.16M |
| FY2023ended Dec 31, 2023 | $0.00 | — | −$198.13M | — | −$2.18 | −$174.14M |
| FY2022ended Dec 31, 2022 | $0.00 | — | −$121.82M | — | −$4.19 | −$147.92M |
| FY2021ended Dec 31, 2021 | $0.00 | −100.0% | −$165.37M | — | −$14.19 | −$38.23M |
| FY2020ended Dec 31, 2020 | $5.21M | — | −$3.41M | −65.5% | −$1.91 | −$6.18M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | $838.00K | −$46.08M | — |
| Q3 FY2025ended Sep 30, 2025 | $1.23M | −$50.58M | −$0.32 |
| Q2 FY2025ended Jun 30, 2025 | $1.12M | −$52.59M | −$0.41 |
| Q1 FY2025ended Mar 31, 2025 | $1.45M | −$51.89M | −$0.40 |
| Q4 FY2024ended Dec 31, 2024 | $2.18M | −$42.28M | — |
| Q3 FY2024ended Sep 30, 2024 | $209.00K | −$52.52M | −$0.44 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | −$0.46 |
| Q1 FY2024ended Mar 31, 2024 | $591.00K | — | −$0.44 |
Company profile
- Name
- Prime Medicine, Inc.
- Ticker
- PRME
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 60 First St., Cambridge, MA 02141
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001894562
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jul 8, 2026
- Jun 8, 2026
- May 7, 2026
- May 7, 2026
- Apr 16, 2026
- Mar 3, 2026
Frequently asked questions
What is Prime Medicine's stock price?
Prime Medicine (PRME) closed at $767.79 on Oct 9, 2026, down 0.26% from the previous close of $769.78.
What is Prime Medicine's market cap?
Prime Medicine's market cap is $138.77B, based on a share price of $767.79 and 180.7M shares outstanding as of Jun 30, 2026.
How much revenue does Prime Medicine make?
Prime Medicine reported revenue of $4.63M for fiscal 2025, up 55.28% from fiscal 2024.
Does Prime Medicine pay a dividend?
Prime Medicine's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Prime Medicine, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures